Alnylam Pharmaceuticals (ALNY) Competitors $459.66 +2.71 (+0.59%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$445.52 -14.14 (-3.08%) As of 10/10/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY vs. AMGN, GILD, VRTX, REGN, BIIB, UTHR, INCY, NBIX, IONS, and EXASShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Its Competitors Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences Ionis Pharmaceuticals Exact Sciences Alnylam Pharmaceuticals (NASDAQ:ALNY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Is ALNY or AMGN more profitable? Amgen has a net margin of 18.96% compared to Alnylam Pharmaceuticals' net margin of -12.96%. Amgen's return on equity of 174.71% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.96% -273.52% -7.39% Amgen 18.96%174.71%13.12% Which has more risk & volatility, ALNY or AMGN? Alnylam Pharmaceuticals has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Do institutionals & insiders hold more shares of ALNY or AMGN? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer ALNY or AMGN? Alnylam Pharmaceuticals currently has a consensus target price of $457.16, suggesting a potential downside of 0.54%. Amgen has a consensus target price of $309.42, suggesting a potential upside of 6.65%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 24 Buy rating(s) 0 Strong Buy rating(s) 2.82Amgen 1 Sell rating(s) 11 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.35 Which has better earnings & valuation, ALNY or AMGN? Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.46B24.47-$278.16M-$2.47-186.10Amgen$33.42B4.67$4.09B$12.2323.72 Does the media refer more to ALNY or AMGN? In the previous week, Amgen had 44 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 67 mentions for Amgen and 23 mentions for Alnylam Pharmaceuticals. Amgen's average media sentiment score of 1.08 beat Alnylam Pharmaceuticals' score of 0.68 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 7 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 45 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive SummaryAmgen beats Alnylam Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.25B$3.33B$6.04B$10.25BDividend YieldN/A2.31%5.73%4.79%P/E Ratio-186.1022.2586.2226.56Price / Sales24.47458.84622.64133.27Price / CashN/A44.9825.7330.17Price / Book883.9610.2112.866.52Net Income-$278.16M-$52.40M$3.31B$276.31M7 Day Performance1.69%0.20%-0.70%-2.91%1 Month Performance-1.34%13.49%8.35%4.15%1 Year Performance61.67%27.29%79.23%30.14% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals3.9574 of 5 stars$459.66+0.6%$457.16-0.5%+61.7%$60.25B$2.46B-186.102,230Analyst ForecastAMGNAmgen4.5496 of 5 stars$294.12-1.3%$309.70+5.3%-11.6%$160.37B$34.92B24.0528,000Positive NewsAnalyst DowngradeAnalyst RevisionGILDGilead Sciences4.8778 of 5 stars$113.58+0.8%$117.17+3.2%+37.9%$140.93B$28.75B22.6317,600Trending NewsAnalyst RevisionVRTXVertex Pharmaceuticals4.8269 of 5 stars$402.90-0.1%$493.81+22.6%-15.3%$103.30B$11.02B28.806,100Positive NewsAnalyst ForecastAnalyst RevisionREGNRegeneron Pharmaceuticals4.7318 of 5 stars$585.48-2.4%$817.67+39.7%-44.4%$62.05B$14.21B14.7615,106Trending NewsAnalyst ForecastAnalyst RevisionBIIBBiogen4.6045 of 5 stars$154.05-3.6%$180.04+16.9%-22.2%$23.44B$10.00B14.737,605Trending NewsAnalyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.1954 of 5 stars$453.28+0.0%$449.57-0.8%+22.8%$20.44B$3.08B17.691,305Analyst ForecastInsider TradeINCYIncyte4.3726 of 5 stars$87.23+0.4%$83.64-4.1%+26.7%$17.03B$4.24B19.832,617NBIXNeurocrine Biosciences4.7601 of 5 stars$139.43+1.8%$161.89+16.1%+18.3%$13.83B$2.51B41.251,800IONSIonis Pharmaceuticals3.4441 of 5 stars$69.02-0.2%$75.29+9.1%+82.0%$11.00B$944.05M-37.511,069Trending NewsEXASExact Sciences4.4148 of 5 stars$57.63+1.6%$68.52+18.9%-17.8%$10.91B$2.76B-10.617,000Trending NewsInsider Trade Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Ionis Pharmaceuticals Alternatives Exact Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNY) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
